Life Sciences
Huma’s digital phenotyping and biomarker capabilities can provide more comprehensive, objective, and continuous pictures of human function in health and disease. This data is advancing predictive health and personalised medicine and is improving the efficiency of clinical trials.
The current situation
In research and clinical care, a participant or patient’s disease progression is observed through episodic clinical visits, meaning fluctuations in disease progression are not always captured. Assessments are also often observational rather than quantitative, resulting in a subjective analysis of the disease state or treatment outcome.
There is an urgent need for more objective, sensitive, and continuous descriptions of disease signs and how patients feel and function.
Huma’s portfolio of digital phenotyping capabilities and digital biomarkers bring precision and holistic insights into drug development and clinical practice, and can enable personalised approaches to treatment.
Patients spend the majority of their time outside of a clinical setting. Traditional clinical visits limit observations to episodic assessments, potentially missing critical insights into disease signs and progression 1.
Smartphones and wearables can continuously collect health information and provide a more comprehensive picture of disease burden and progression, that would otherwise be hidden in standard clinical visits.
Many assessments performed in the clinical setting, such as self-reported information and rating scales, are subjective, rather than objective 2.
Digital biomarkers provide unbiased, objective assessments of clinical status and therapeutic effects, and can enable a predictive and personalised approach to treatment and care.
Traditional clinical biomarkers can be invasive and expensive to measure, requiring trained personnel in clinical practice 3.
Digital biomarkers provide unbiased, objective assessments of clinical status and therapeutic effects, and can enable a predictive and personalised approach to treatment and care.
Huma is developing a portfolio of digital biomarkers and digital measures across a number of disease areas, both independently and in partnership with other life science companies.
These measures are being used by our life science and healthcare partners to advance diagnosis, prognosis, tailor treatment decisions, and improve the assessment of therapeutics outcomes in both clinical trials and practice.
Huma has developed a portfolio of digital tools and capabilities that utilise the sensors and data collection capabilities of personal smartphones, wearables, and other connected devices. We are deploying these tools through our digital platforms to help our partners build-up a comprehensive, real-life digital picture (or digital phenotype), and how an individual is feeling and functioning.
Our offering
Less invasive assessments, provided outside of a clinical setting, reducing the burden on participants/carers.
Improved patient monitoring, enabling more holistic, precise measurements of disease signs and/or treatment outcome.
More accessible and patient-centric.
Objective, precise, and unbiased clinical trial endpoints, that potentially increase the opportunity for success, and reduce study timelines and size.
More holistic pictures of disease signs and symptoms, that uncover novel insights, enabling the development of more personalised treatments.
Less invasive assessments, that reduce the burden on participants to engage in trials, improving recruitment and retention.
Less invasive assessments, provided outside of a clinical setting, reducing the burden on participants/carers.
Improved patient monitoring, enabling more holistic, precise measurements of disease signs and/or treatment outcome.
More accessible and patient-centric.
Objective, precise, and unbiased clinical trial endpoints, that potentially increase the opportunity for success, and reduce study timelines and size.
More holistic pictures of disease signs and symptoms, that uncover novel insights, enabling the development of more personalised treatments.
Less invasive assessments, that reduce the burden on participants to engage in trials, improving recruitment and retention.
Why Huma?
Extensive in-house data science team
with a deep understanding of and
expertise in extracting novel insights
from high dimensional datasets.
Deep understanding of the importance of
user experience research and design to
ensure users can reliably operate digital
biomarker modules and deliver solutions
that easily fit into their daily lives.
Strong understanding of the evolving
regulatory landscape for digital
biomarkers and measures
Wide network of leading researchers,
clinical experts and research-grade
patient data to efficiently refine and
validate digital measures.
Our digital measures are all built
under a Quality Management System
compliant with global security, privacy
and regulatory requirements.
Partnerships with top 10 pharma
companies and leading academic
research institutions to develop novel
digital measures.
Digital biomarker solutions available
on both iOS and Android, and
integrate and gather data from 400+
wearables devices.
Extensive in-house data science team with a deep understanding of and expertise in extracting novel insights from high dimensional datasets.
Deep understanding of the importance of user experience research and design to ensure users can reliably operate digital biomarker modules and deliver solutions that easily fit into their daily lives.
Strong understanding of the evolving regulatory landscape for digital biomarkers and measures.
Wide network of leading researchers, clinical experts and research-grade patient data to efficiently refine and validate digital measures.
Our digital measures are all built under a Quality Management System compliant with global security, privacy and regulatory requirements.
Partnerships with top 10 pharma companies and leading academic research institutions to develop novel digital measures.
Digital biomarker solutions available on both iOS and Android, and can integrate and gather data from 400+ wearables devices.
Case Studies
In partnership with Johnson & Johnson, Huma are further validating and commercialising a digital biomarker focussed on early detection and monitoring of Alzheimer’s disease, through assessing verbal learning via voice recognition technology.
Case Studies
Huma have partnered with Johns Hopkins to develop a COVID-19 severity risk score that assesses an individual’s risk of developing severe complications.
The COVID-19 Risk Score is based on a meta-analysis of 1,800 medical papers and combines 31 criteria and risk factors associated with COVID-19.
Case Studies
As part of a companion app to support patients with pulmonary arterial hypertension, Huma together with Bayer, are further validating a digital version of the clinical Timed Up and Go test, which measures a person’s mobility.
Case Studies
Huma is developing a technology that allows a patient to capture their breathing rate utilising the motion sensors of the smartphone. Tracking changes in breathing gives patients and their clinicians a chance to spot early warning signs of deterioration in a range of conditions, including COVID-19.
Case Studies
Huma and Tencent Medical AI Lab partnered to evaluate a novel motion capture and Tencent's AI technology to assess motor functions of people with Parkinson's disease in the real-world setting, using smartphones.
The study aims to advance the early diagnosis of Parkinson's disease, screening, and daily monitoring of disease progression.
Contact us
Understanding Commonly Encountered Limitations in Clinical Research: An Emergency Medicine Resident’s Perspective. Jones, Christopher W. and Platts-Mills, Timothy F. MD (2011) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3539753/
Traditional and Digital Biomarkers: Two Worlds Apart.Babrak, L.M. and Menetski, J. (2019)
Digital R&D: The Next Frontier for Biopharmaceuticals. McKinsey & Company (2017)
https://www.mckinsey.com/~/media/mckinsey/industries/pharmaceuticals%20and%20medical%20products/our%20insights/digital%20rd%20the%20next%20frontier%20for%20biopharmaceuticals/digitalrdthenextfrontierforbiopharma.pdf